翰森製藥(03692.HK)：“培莫沙肽注射液”新適應症上市許可申請獲國家藥監局受理

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

翰森製藥(03692.HK)：“培莫沙肽注射液”新適應症上市許可申請獲國家藥監局受理

格隆匯 05-10 08:27

格隆匯5月10日丨翰森製藥(03692.HK)發佈公吿，由公司附屬公司江蘇豪森藥業集團有限公司自主研發的1類創新藥“培莫沙肽注射液”(原名稱：培化西海馬肽注射液)的新適應症上市許可申請獲中國國家藥品監督管理局受理，擬用於治療未接受促紅細胞生成素治療的非透析慢性腎病患者的貧血。

翰森製藥(03692.HK)

Relevant Stocks

翰森製藥(03692.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

翰森製藥(03692.HK)：“培莫沙肽注射液”新適應症上市許可申請獲國家藥監局受理

Services

About Us

Agreement Statement